- Home
- INTR vs WGS Comparison
INTR vs WGS Comparison
Compare INTR & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INTR | WGS |
|---|---|---|
| Founded | 1994 | 2017 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | | Retail: Computer Software & Peripheral Equipment |
| Sector | | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.6B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | INTR | WGS |
|---|---|---|
| Price | $8.49 | $134.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $7.78 | ★ $138.13 |
| AVG Volume (30 Days) | ★ 2.3M | 389.0K |
| Earning Date | 02-05-2026 | 02-17-2026 |
| Dividend Yield | ★ 0.94% | N/A |
| EPS Growth | ★ 51.09 | N/A |
| EPS | ★ 0.51 | 0.07 |
| Revenue | ★ $1,056,044,206.00 | $402,190,000.00 |
| Revenue This Year | $85.08 | $41.17 |
| Revenue Next Year | $25.23 | $23.53 |
| P/E Ratio | ★ $16.49 | $1,804.77 |
| Revenue Growth | 34.63 | ★ 50.50 |
| 52 Week Low | $4.00 | $55.17 |
| 52 Week High | $10.22 | $170.87 |
Technical Indicators
Market Signals| Indicator | INTR | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 49.68 | 43.53 |
| Support Level | $8.44 | $125.46 |
| Resistance Level | $8.66 | $143.95 |
| Average True Range (ATR) | 0.21 | 6.43 |
| MACD | 0.05 | -1.91 |
| Stochastic Oscillator | 73.62 | 31.90 |
Price Performance
Historical ComparisonAbout INTR Inter & Co. Inc.
Inter & Co Inc operates as a digital bank. The company's segment includes Banking & Spending; Investments; Insurance Brokerage; and Inter Shop. It generates maximum revenue from the Banking & Spending segment which comprises a wide range of banking products and services, such as checking accounts, cards, deposits, loans and advances, and other services, which are available to the clients by means of Inter's mobile application.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.